Skip to content
AACR 2026 现场信号· @ · X·· 2026-04-22Score60
Body · original

🔬 TRUST pooled data presented at #AACR26 showed 46.1-month PFS and 89.8% ORR with taletrectinib in TKI-naive, ROS1+ metastatic #NSCLC. 🫁

🎥 Watch Dr Lyudmila Bazhenova (@UCSDHealth) highlight these data and future research directions here: https://t.co/LNchWclcoc https://t.co/STR3hIImzt

Heat 4 · 3 likes · 0 replies · 1 repost

Conference abstracts
CT248NCT05118789matched by 药名 taletrectinib
Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib

Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, Adrianus Johannes de Langen, Alice T. Shaw, Jonathan W. Riess, Marina Garassino, Elaine Shum, Christina S. Baik, Jessica R. Bauman, D. Ross Camidge, Chien-Chung Lin, Gee-Chen Chang, Dong-Wan Kim, Myung-Ju Ahn, Ji-Youn Han, Kiichiro Ninomiya, Ryo Ariyasu, Ross Andrew Soo, Sanjay Popat, Jürgen Wolf, Maria Rosario García Campelo, Vivek A. Upadhyay, Stephen V. Liu

Read the abstract →

Source: AACR 2026 现场信号 · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org